A groundbreaking study published in Cardiovascular Research unveils AB-Biotics’ AB-Life probiotic strains’ profound cardiometabolic benefits in combating atherosclerotic cardiovascular diseases (ACVDs). Led by AB-Biotics, the research demonstrates how AB-Life, containing Lactiplantibacillus plantarum strains, reduces LDL particle sizes and apolipoproteins, pivotal biomarkers in atherosclerosis development. The study highlights the probiotics’ role in bile acid metabolism, lowering LDL-C and ApoB protein levels, while also improving gut microbiota composition and offering protection against dyslipidemia. This discovery underscores the potential of probiotics in enhancing cardiovascular health and prompts further investigation into their therapeutic applications.
Dark Chocolate: A Potential Ally Against Type 2 Diabetes
December 7, 2024
